
McKesson Corporation
MCK
Updated: 23/09/2026, 02:25:54
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
No summaries found.
The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.
- Share price
- $891.23
- Market cap
- $104.34B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Brian S. Tyler
- Employees
- 42,300
- IPO date
- 10/11/1994
- Beta
- 0.307
- Last dividend
- $0.00
- Day range
- $882.97 – $897.46
- 52-week range
- $714.00 – $999.00
- 1-day performance
- 0.54%
- 1-year performance
- 24.82%
- Current drawdown (1Y)
- -10.79%
- CIK
- 0000927653
- CUSIP
- 58155Q103
- ISIN
- US58155Q1031
- Created
- 07/12/2025, 05:11:32
- Last update
- 23/09/2026, 02:25:54
Track McKesson Corporation with an AI analyst
See which prediction-market events move MCK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research • STOCK • 10/06/2026, 12:01:24
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
Zacks Investment Research • STOCK • 08/06/2026, 12:51:21
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research • STOCK • 27/05/2026, 12:00:26
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
Zacks Investment Research • STOCK • 22/05/2026, 15:21:07
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research • STOCK • 14/05/2026, 12:01:34
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 17:10:48
McKesson Q4 Earnings Call Highlights
MarketBeat • STOCK • 11/05/2026, 17:09:43
MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up
Zacks Investment Research • STOCK • 08/05/2026, 13:51:07
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 23:01:17
Compared to Estimates, McKesson (MCK) Q4 Earnings: A Look at Key Metrics
Zacks Investment Research • STOCK • 07/05/2026, 21:01:13
McKesson (MCK) Surpasses Q4 Earnings Estimates
Zacks Investment Research • STOCK • 07/05/2026, 20:55:12
Should You Buy, Sell, or Hold McKesson Before Q4 Earnings?
Zacks Investment Research • STOCK • 07/05/2026, 16:35:45